Evidence map›Paper›PMID 32650784›Full record

ArticleMalaria journal2020

Therapeutic efficacy of artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Chewaka District, Ethiopia.

Abdulhakim Abamecha, Daniel Yilma, Wondimagegn Addisu, Hassan El-Abid, Achim Ibenthal, Harald Noedl, Delenasaw Yewhalaw, Mohieddine Moumni, Alemseged Abdissa

Open access · goldAbstract read
In one paragraph

Article in Malaria journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 3 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 2 countries.

Abdulhakim AbamechaSchool of Medical Laboratory Science, Institute of Health, Jimma University, Jimma, Ethiopia. abdulhakimbamecha@gmail.com.ORCID http://orcid.org/0000-0003-4501-4759
Daniel YilmaDepartment of Internal Medicine, Institute of Health, Jimma University, Jimma, Ethiopia.
Wondimagegn AddisuSchool of Medical Laboratory Science, Institute of Health, Jimma University, Jimma, Ethiopia.
Hassan El-AbidBiotechnology and Bio-Resources Development Laboratory, Faculty of Sciences, Moulay Ismail University, Meknes, Morocco.
Achim IbenthalFaculty of Science and Art, HAWK University, Gottingen, Germany.
Harald NoedlMalaria Research Initiative Bandarban (MARIB), Vienna, Austria.
Delenasaw YewhalawSchool of Medical Laboratory Science, Institute of Health, Jimma University, Jimma, Ethiopia.
Mohieddine MoumniBiotechnology and Bio-Resources Development Laboratory, Faculty of Sciences, Moulay Ismail University, Meknes, Morocco.
Alemseged AbdissaSchool of Medical Laboratory Science, Institute of Health, Jimma University, Jimma, Ethiopia.
Jimma University · ET

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe efficacy of artemether-lumefantrine (AL) for treatment of uncomplicated Plasmodium falciparum malaria in south-western Ethiopia is poorly documented. Regular monitoring of drug efficacy is an important tool for supporting national treatment policies and practice. This study investigated the therapeutic efficacy of AL for the treatment of P. falciparum malaria in Ethiopia.

methodsThe study was a one-arm, prospective, evaluation of the clinical and parasitological, responses to directly observed treatment with AL among participants 6 months and older with uncomplicated P. falciparum malaria. Real-time polymerase chain reaction (PCR) and nested PCR reaction methods were used to quantify and genotype P. falciparum. A modified protocol based on the World Health Organization 2009 recommendations for the surveillance of anti-malarial drug efficacy was used for the study with primary outcomes, clinical and parasitological cure rates at day-28. Secondary outcomes assessed included patterns of fever and parasite clearance. Cure rate on day-28 was assessed by intention to treat (ITT) and per protocol (PP) analysis. Parasite genotyping was also performed at baseline and at the time of recurrence of parasitaemia to differentiate between recrudescence and new infection.

resultsOf the 80 study participants enrolled, 75 completed the follow-up at day-28 with ACPR. For per protocol (PP) analysis, PCR-uncorrected and-corrected cure rate of AL among the study participants was 94.7% (95% CI 87.1-98.5) and 96% (95% CI 88.8-99.2), respectively. For intention to treat (ITT) analysis, the cure rate was 90% (95% CI 88.8-99.2). Based on Kaplan-Meier survival estimate, the cumulative incidence of failure rate of AL was 3.8% (95% CI 1.3-11.4). Only three participants 3.8% (95% CI 0.8-10.6) of the 80 enrolled participants were found to be positive on day-3. The day three-positive participants were followed up to day 28 and did not correspond to treatment failures observed during follow-up. Only 7.5% (6/80) of the participants were gametocyte-positive on enrollment and gametocytaemia was absent on day-2 following treatment with AL.

conclusionsThe therapeutic efficacy of AL is considerably high (above 90%). AL remained highly efficacious in the treatment of uncomplicated malaria in the study area resulted in rapid fever and parasite clearance as well as low gametocyte carriage rates despite the use of this combination for more than 15 years.

Indexed as

AdolescentAdultAntimalarialsArtemether, Lumefantrine Drug CombinationChildChild, PreschoolEthiopiaFemaleHumansMalaria, FalciparumMaleMiddle AgedProspective StudiesYoung AdultAntimalarialsArtemether, Lumefantrine Drug CombinationArtemether-lumefantrineEthiopiaTherapeutic efficacyUncomplicated malaria

Identifiers

PMID32650784
PMCPMC7350688
OpenAlexW3041365141

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.